common.study.topics.clinical

Levomilnacipran in Healthy Males

common.study.values.description

Levomilnacipran in Healthy Males

Levomilnacipran is an antidepressant currently approved in Canada to treat Major Depressive Disorder (MDD). Thirty-six healthy male participants will receive escalating doses of levomilnacipran, duloxetine, or placebo every 7 days (+/- 1 day) throughout a 20 - 28 day period. After each dose escalation study participants will be asked to come to the clinic to conduct the necessary tests - these will include tyramine pressor tests as well as blood draws. The results of this study will allow the investigators to determine the dose(s) of levomilnacipran at which reuptake inhibition of norepinephrine and serotonin (chemicals utilized by nerve cells to transmit information to other cells) is achieved.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Levomilnacipran

Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.

Drug - Duloxetine

Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.

Drug - Placebos

Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.

participant.views.study.view.additional

participant.views.study.view.scientific-title

Effectiveness of the Norepinephrine and Serotonin Reuptake Inhibitor Levomilnacipran in Healthy Males

common.study.values.clinical-trial-id

NCT03249311

participant.views.study.view.id

Rb406b